Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence.

Graham DY, Lee YC, Wu MS.

Clin Gastroenterol Hepatol. 2014 Feb;12(2):177-86.e3; Discussion e12-3. doi: 10.1016/j.cgh.2013.05.028. Epub 2013 Jun 8.

3.

High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.

Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, Lu H.

Helicobacter. 2010 Jun;15(3):233-8. doi: 10.1111/j.1523-5378.2010.00758.x.

PMID:
20557366
4.

Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.

Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, Perez-Gallardo B, Dueñas-Sadornil C, Hernandez-Alonso M, Gonzalez-Garcia G, Mateos-Rodriguez JM, Fernandez-Bermejo M, Gisbert JP.

Helicobacter. 2012 Aug;17(4):269-76. doi: 10.1111/j.1523-5378.2012.00947.x. Epub 2012 Mar 30.

PMID:
22759326
5.

Evidence-based recommendations for successful Helicobacter pylori treatment.

Wu JY, Liou JM, Graham DY.

Expert Rev Gastroenterol Hepatol. 2014 Jan;8(1):21-8. doi: 10.1586/17474124.2014.859522. Epub 2013 Dec 2. Review.

PMID:
24410470
6.

Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.

Gisbert JP, Molina-Infante J, Marin AC, Vinagre G, Barrio J, McNicholl AG.

Scand J Gastroenterol. 2013 Jun;48(6):652-6. doi: 10.3109/00365521.2013.786132. Epub 2013 Apr 5.

PMID:
23556551
7.

Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.

Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, Xiao S, Lu H.

Clin Gastroenterol Hepatol. 2013 Jul;11(7):802-7.e1. doi: 10.1016/j.cgh.2013.01.008. Epub 2013 Jan 29.

PMID:
23376004
9.

The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.

Uygun A, Kadayifci A, Safali M, Ilgan S, Bagci S.

J Dig Dis. 2007 Nov;8(4):211-5.

PMID:
17970879
10.

Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.

Gisbert JP, Pajares JM.

Aliment Pharmacol Ther. 2002 Jun;16(6):1047-57. Review.

11.

'Rescue' therapies for the management of Helicobacter pylori infection.

Di Mario F, Cavallaro LG, Scarpignato C.

Dig Dis. 2006;24(1-2):113-30. Review.

PMID:
16699270
12.

Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.

Lee JM, Breslin NP, Hyde DK, Buckley MJ, O'Morain CA.

Aliment Pharmacol Ther. 1999 Apr;13(4):489-96.

13.

Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study.

Pilotto A, Franceschi M, Rassu M, Leandro G, Bozzola L, Furlan F, Di Mario F.

Dig Liver Dis. 2000 Nov;32(8):667-72.

PMID:
11142574
14.

Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures.

Treiber G, Ammon S, Malfertheiner P, Klotz U.

Helicobacter. 2002 Aug;7(4):225-31.

PMID:
12165029
15.
16.

High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study.

Peitz U, Sulliga M, Wolle K, Leodolter A, Von Arnim U, Kahl S, Stolte M, Börsch G, Labenz J, Malfertheiner P.

Aliment Pharmacol Ther. 2002 Feb;16(2):315-24.

17.
18.

Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies.

Bochenek WJ, Peters S, Fraga PD, Wang W, Mack ME, Osato MS, El-Zimaity HM, Davis KD, Graham DY; Helicobacter pylori Pantoprazole Eradication (HELPPE) Study Group.

Helicobacter. 2003 Dec;8(6):626-42. Erratum in: Helicobacter. 2004 Apr;9(2):183.

PMID:
14632678
19.

Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea.

Kim YS, Kim SJ, Yoon JH, Suk KT, Kim JB, Kim DJ, Kim DY, Min HJ, Park SH, Shin WG, Kim KH, Kim HY, Baik GH.

Aliment Pharmacol Ther. 2011 Nov;34(9):1098-105. doi: 10.1111/j.1365-2036.2011.04843.x. Epub 2011 Sep 19.

20.

Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy.

Prasertpetmanee S, Mahachai V, Vilaichone RK.

Helicobacter. 2013 Aug;18(4):270-3. doi: 10.1111/hel.12041. Epub 2013 Jan 29.

PMID:
23356886
Items per page

Supplemental Content

Write to the Help Desk